AI

    Flagship Pioneering commits £100m to a London lab to build AI-native companies as it targets a further £500m from partners

    Flagship Pioneering, the US venture creator behind Moderna, has committed an initial £100m to Flagship Origination Lab, U.K., a London unit that will conceive, fund and own AI-native platform companies. The firm expects to scale the commitment by drawing in a further £500m through partnerships.

    T

    The Cap Table

    17 November 20263 min read
    Flagship Pioneering commits £100m to a London lab to build AI-native companies as it targets a further £500m from partners

    Flagship Pioneering, the US venture creator behind Moderna, has committed an initial £100m to Flagship Origination Lab, U.K., a London unit that will conceive, fund and own AI-native platform companies. The firm expects to scale the commitment by drawing in a further £500m through partnerships.

    The Cambridge, Massachusetts group announced the lab on 16 November. It is the first dedicated company-creation unit Flagship has set up outside the US, and the first time its Flagship Labs model has been extended beyond its home base.

    Flagship has created more than 130 companies over 25 years. Its current ecosystem of more than 40 businesses includes Moderna, Generate Biomedicines, Lila Sciences, Inari, Tessera Therapeutics and Valo Health. The firm said it had $14bn of assets under its direction as of its last capital raise in July 2024.

    How the money will be used

    The £100m is not a conventional fund writing cheques into outside start-ups. Flagship Labs invents the science in-house, forms the company and provides the founding capital, which means Flagship typically sits at the top of the cap table from day one rather than buying in at seed or Series A.

    The London lab will follow that template. It will originate companies working on human and planetary health and other areas of science and technology, with AI at the core of each platform. Flagship plans to recruit and train an initial team of about 50 scientist-entrepreneurs and operators in the UK.

    Noubar Afeyan, Flagship's founder and chief executive, said the £100m was an initial commitment that the firm anticipates growing through partnership to attract an additional £500m. If that target is met, the total pool behind the lab would reach about £600m. The identity of any partners was not disclosed.

    Three years in the making

    The move builds on a London office Flagship opened in 2023, when it signed a memorandum of understanding with the UK government. Since then it has launched Quotient Therapeutics, its first transatlantic company, and Flagship-founded businesses such as Generate:Biomedicines have run clinical trials in the UK.

    Avak Kahvejian, president of Flagship Labs and a general partner at Flagship Pioneering, cited the UK's science base, clinical-trial infrastructure, genomics and health-data assets and regulatory environment as reasons for choosing it as the first expansion market.

    Science minister Chris McDonald welcomed the commitment, saying it would help turn research in AI and life sciences into new businesses and jobs.

    What it means for the UK market

    The lab adds a new type of company-builder to a UK deep-tech scene that has relied heavily on university spinout offices and specialist funds such as Oxford Science Enterprises and IP Group. Because Flagship founds and owns its companies, early equity in the businesses it creates in London will be concentrated with Flagship rather than spread across a syndicate of local seed investors.

    The first test will be how quickly the lab hires its initial cohort and announces its first companies, and whether the £500m of partner capital materialises.


    Original source: PR Newswire (Flagship Pioneering) — https://www.prnewswire.com/news-releases/flagship-pioneering-launches-flagship-origination-lab-in-london-to-create-ai-native-platform-companies-in-the-uk-302939394.html

    T

    Written by

    The Cap Table

    Stay in the loop

    Get the biggest stories from the UK startup ecosystem straight to your inbox. No spam, just what matters.

    Related stories